MANF Protein Composition for Fat Decomposition and Neuronal Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compositions fail to effectively utilize Mesencephalic astrocyte-derived neurotrophic factor (MANF) and other proteins like APLN, GDF11, TIMP2, and THBS4 to address aging-related issues and neurological diseases.
Innovation Solution
Pharmaceutical and cosmetic compositions containing MANF, APLN, GDF11, TIMP2, and THBS4 are developed to promote fat decomposition, muscle formation, hyaluronic acid production, and inhibit protein accumulation and neuronal cell death, among other therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MANF and related proteins are used in compositions, then therapeutic effects for aging and neurological diseases are improved, but composition complexity increases
Solution Approach 1:
The patent combines multiple proteins (MANF, APLN, GDF11, TIMP2, THBS4, CXCL4) into a single pharmaceutical or cosmetic composition. This merging approach allows the composition to deliver multiple therapeutic effects simultaneously - fat decomposition, muscle formation, neuronal protection, and anti-aging benefits - while managing the complexity through a unified formulation strategy rather than separate treatments.
2Adaptability or versatility
If multiple proteins (MANF, APLN, GDF11, TIMP2, THBS4) are combined in compositions, then versatility of therapeutic applications is improved, but manufacturing complexity increases
Solution Approach 1:
The composition is designed with universal applicability across multiple therapeutic indications including neurological diseases (Alzheimer's, Parkinson's, ALS), metabolic disorders (obesity, diabetes), and anti-aging applications. The same formulation containing MANF and related proteins addresses diverse conditions through their complementary biological activities, eliminating the need for separate specialized treatments for each condition.
Solution Approach 2:
The patent employs a composite protein formulation where MANF is combined with other neurotrophic factors and protective proteins (APLN, GDF11, TIMP2, THBS4, CXCL4). This composite approach leverages the synergistic effects of multiple proteins to achieve enhanced therapeutic outcomes across different disease models while managing manufacturing through integrated production protocols.
3Reliability
If MANF is used to promote fat decomposition and muscle formation, then metabolic health is improved, but dosage precision requirements increase
Solution Approach 1:
The patent optimizes the concentration parameters of MANF and accompanying proteins in the composition to achieve effective therapeutic doses. By carefully controlling the amounts of each protein component and their ratios, the formulation achieves reliable metabolic effects including fat decomposition and muscle formation while maintaining manufacturable dosage specifications.
Data Source
AI summary
A method for decomposing fat, promoting production of prostacyclin or cyclic adenosine monophosphate (cAMP), promoting production of hyaluronic acid in chondrocytes, inducing differentiation of a myoblast to a myotube, and/or treating a lifestyle-related disease or an adult-onset disease, including administering an effective amount of MANF to a subject. A method for inhibiting accumulation of amyloid beta, including administering an effective amount of a composition including MANF, APLN, CXCL4, GDF11, THBS4, and/or TIMP2 to a subject.